[{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"tldr","before":"\"In-licenser of Chinese assets including the Nectin-4×TROP2 bispecific ADC AVZO-103 and a CDK2 inhibitor.\"","after":"\"Avenzo in-licenses Chinese assets, including the Nectin-4×TROP2 bispecific ADC AVZO-103 and a CDK2 inhibitor.\""}]},{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/companies.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"targets"}]}]